Regarding annexin A6 (ANxA6), a susceptibility factor for psoriasis, the rs11960458-TT/CT genotype was significantly more likely to be unresponsive to MTX in both short (12 weeks) and long-term (1 year) treatment, whereas the rs960709 and rs13168551 polymorphisms were only associated with short-term efficacy [51]. The gene discussed is ANXA6; the disease is psoriasis.